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The in vitro degradation properties of glutaraldehyde cross-linked albumin and albumin-heparin 
conjugate microspheres (AMS and AHCMS respectively) were evaluated using light microscopy, 
turbidity measurements and heparin release determinations, showing that the microspheres are 
degraded by proteolytic enzymes such as trypsin, proteinase K and lysosomal enzymes. The 
degradation rate was inversely related to the cross-link density of the microspheres. After intrahepatic 
administration of AHCMS, cross-linked with 0.5% glutaraldehyde, to male WaglRij rats by injection 
into a mesenteric vein (intraveno-portal: i.v.p.), the microspheres were entrapped in the hepatic 
vascular system. The AHCMS were entrapped within terminal portal veins predominantly at the 
periphery of the liver. The AHCMS were degraded by cellular enzymatic processes within 2 wk after 
injection, with a half life of approximately 1 d. Biocompatibility of AHCMS and adriamycin-loaded 
AHCMS was evaluated by histological assessment of the mitotic activity of liver parenchym and 
inflammatory response, and by determination of liver damage marker enzymes during 4 wk after 
administration. Liver damage marker enzymes were not increased as compared with controls, nor 
were adverse effects observed upon histological examination. There was no difference in response 
between empty and adriamycin-loaded AHCMS. 
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Albumin-heparin conjugate microspheres (AHCMS) 
have been developed as potential adriamycin (ADR) 
targeting devices for the treatment of, for instance, 
hepatic metastases of colon carcinoma’3 ‘. Treating liver 
metastases using chemoembolization therapy, the drug- 
loaded microspheres are injected into a mesenteric vein 
or into the hepatic artery. It has been shown that 
microspheres of the appropriate size (10-50 pm) are 
predominantly trapped in the vascular system of 
tumours3.4. To achieve adequate therapeutic efficacy, it 
may be necessary to repeat the chemoembolization 
treatment several times. When non-degradable spheres 
are used, accumulation of foreign material in the liver 
occurs. This may cause unnecessary damage to the 
liver. Hence, the AHCMS have to be biodegradable. 
Another important issue in the use of AHCMS in 
chemoembolization therapy is the biocompatibility of 
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the microspheres. Upon implantation of a foreign 
body, a wound healing process due to the trauma 
induced by the implantation procedure is provoked. 
Wound healing processes include an inflammatory 
phase, a proliferative phase and a remodelling phase. 
The acute inflammatory response involves local 
accumulation of inflammatory cells, including neutro- 
phils and monocyteslmacrophages and in some 
instances lymphocytes5,6. This phase usually lasts 
several days, but may be prolonged by the presence of 
a foreign body. Consequently, the inflammatory 
response which remains after 1 wk can be considered 
to be a tissue reaction against the implanted material. 
Chronic inflammatory responses include persistence of 
inflammatory cells around and inside the implant, the 
presence of multinucleated giant cells and persistence 
of a high degree of vascularization. The inflammatory 
phase is generally followed by the formation of a 
fibrotic capsule containing collagen and connective 
tissue cells surrounding the implant6. In general, all 
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implants cause some degree of irritation and the 
success of an implant depends to a large extent on 
minimizing the inflammatory response. Since the 
drug-carrier system should not cause excessive adverse 
tissue reactions, the extent of these tissue reactions 
caused by the AHCMS and ADR-AH~MS was 
evaluated. 
In this paper, the in vitro and in vivo degradation and 
the biocompatibility of AHCMS and ADR-loaded 
AHCMS are described. After implantation of biodegrad- 
able materials, two types of degradation mechanisms 
play an important role: non-enzymatic hydrolysis and 
enzymatic hydrolysis7Y8. The first mechanism involves 
non-enzymatic hy~olysis of a polymer backbone 
which contains hy~olyti~ally unstable bonds such as 
polycarbonates, polyesters, polyurethanes, polyortho- 
esters and polyamides. If a polymer contains bonds 
susceptible to enzymatically ~atalysed hydrolysis, the 
second mechanism generally controls the degradation, 
Since AHCMS are mainly prepared from the endogen- 
ous materials albumin and heparin, it is expected that 
the microspheres can in principle be degraded by 
enzymatic mechanisms. 
fn vitro degradation was investigated using different 
enzymes {trypsin, proteinase K, heparinase) and 
enzyme systems (a cocktail of lysosomal enzymes 
extracted from rat livers, referred to as tritosomes). In 
tivo degradation was investigated after intrahepatic 
administration of AHCMS and ADR-AHCMS in male 
Wag/Rij rats using light and ~ansmission electron 
microscopy* 3iocompatibility of the n~icrospheres was 
determined by measuring the systemic blood levels of 
liver-specific enzymes as a marker for parenchymal 
damage. In addition, the histology of the ‘implantation’ 
site, with regard to acute and chronic in~ammato~ 
responses and increased mitotic activity, the latter 
being a measure for regeneration of damaged tissue, 
was evaluated using light and transmission electron 
microscopy. 
Materials 
Albumin microspheres (AMS) and AHCMS of varying 
cross-linking density were prepared as described 
previously’. AHCMS, cross-linked with 0.5% glutar- 
aldehyde (AHCMSO5) used in the in viva experiments, 
were sieved using IO and 25hm sieves. Sieved 
AH~MSO5 were loaded with ADR (which was a kind 
gift from Farmitalia Carlo Erba, Milan, Italy) up to a 
drug content of 25.4%, as described by Cremers ef al.‘. 
Trypsin, proteinase K and heparinase with specific 
activities of 10100, 11.5 and 23OOU/mg, respectively, 
as indicated by the manufacturer, were obtained 
from Sigma Chemical Company (St. Louis, USA]. 
Tritosomes were prepared by Dr J.M.W. Bouma, at the 
University of Groningen, The Ne~erlands, by a modifi- 
cation of the method of Trouetg as described by Kussen- 
drager et 01. ID The tritosomes (0.52mg/ml of protein) . 
were about TO-fold purified with respect to the liver 
homogenate as determined by measuring the specific 
activity of acid phosphatase. All other materials were 
obtained in the highest possible grade from Merck 
(Darmstadt, ~rmany). 
Animals 
Male Wag/Rij rats, 8-12 wk old and weighing 260 + 
40g at the time of the experiments, were bred at the 
animal department of The Netherlands Cancer 
Institute (Amsterdam, the Ne~erlands) under specific 
pathogen-gee (SPF) conditions. The animals were kept 
on a 12 h light-22 h dark cycle and fed standard rat 
chow and plain tap water ad libitum. 
1~ vitro degradation of AMS and AI-EMS 
To determine the influence of the microsphere stabiliz- 
ation procedure on the degradation rate, preliminary 
experiments with AMS, cross-linked under various 
conditions (listed in Tuble- f), were carried out. AMS 
(5.0mg) were resuspended in 1Oml of phosphate- 
buffered saline (PBS, pH 7.4), containing 0.1% v/v 
Tween 80. In wells of a 96-well microtitre plate, 
0.05ml of an enzyme solution of trypsin or proteinase 
K (5mgfml PBSITw) was added to 0.05 ml of a 
microsphere suspension. The mixture was incubated 
at 37°C. At several time points (5, 15, 30, 60, 90, 120, 
150, 300, 600, 1440 and 288Omin), the wells were 
examined using a light microscope and the degrada- 
tion time was taken as the time at which no single 
microspheres could be further detected. 
In the second set of in vitro degradation experiments, 
3 mg of AHCMS or AMS were resuspended in 3 ml of 
enzyme solution and kept at 37°C in a shaking bath. 
Enzyme solutions of proteinase K (0.5-5 @g/ml PBS) or 
trypsin (0.01-0.1 mglml PBS) were used; the activity of 
the latter solutions was also tested using an N-benzoyl- 
L-arginine-ethyl ester (BAEE) assay as described by 
Bergmeyerl*. At set time points, ranging from 5 min to 
24 h, the turbidity of the suspension was measured at a 
wavelength of 580 nm using a Uvikon 930 spe~~ophot- 
ometer (Kontron Instruments, Rotkreuz, Switzerland). 
At each time point, 150~1 of the microsphere suspen- 
sion were ~ansferred to a 1.5 ml ~ppendorf~~ cup and 
centrifuged at 12 000 r.p.m. for 10 s. Then 100 ~1 of the 
supernatant were taken and used for heparin determi- 
nation using the metachromic azure A assay, described 
Table 1 Degradation time’ of albumin microspheres in 
enzyme systems 
Type Cross- Cross- Trypsin Proteinase K 
linker link jmin) (min) 
cont. (%) time [h) 
AMSO2I 0.2 1 30 5 
AMSOS 0.5 1 90 30 
AMSlO 1.0 1 1440 120 
Ah&15 1.5 1 2880 7440 
AMSBO 3.0 1 >2880 1440 
AMSO!Y&05$ 0.5 0.5 30 30 
AMS05-15 0.5 1.5 150 120 
AMS0.5-30 0.5 3 150 120 
‘Time at which single microspheres could no longer be detected using a light 
microscope. 
‘Number in codes refers to giutaraldehyde concentration. 
tNumbers m codes refer to glutaraldehyde concentration snd cross-link time, 
respectively. 
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by Jacques and Wollin”, 
a1.13. 
as rn~~i~ed by Her-mink et 
The heparin release is ex&essed as Asm. The 
enzyme in the microsphere-containing residue remain- 
ing after centrifugation was inactivated by the addition 
of 1 ml acetic acid buffer (pH 4). These samples were 
stored at -20°C until light microscopic analysis. 
Degradation of AMS and AHCMS was also followed 
using a flow cytometer (FAGStar+, Beckton & Dickin- 
son, Mountain View, CA, USA). The enzyme solution 
(0.05 ml) containing proteinase K (5 mglml), heparin- 
ase (0.025mglml) or tritosomal enzymes was added to 
0.5 ml of a microsphere suspension containing 1.0 mg 
of microspheres/ml of PBS. At set time points varying 
between 4 h and 11 d, depending on the enzyme, the 
size distributions of the microspheres were 
determined. In this experiment the time point at which 
75% of the particles was smaller than 10pm was taken 
as a measure of the degradation time. 
Intrahepatic degradation and biocompatibility of 
AHCMS 
Approximately 5 mg of empty or ADR-loaded AHCMS, 
which were cross-linked with 0.5% glutaraldehyde 
(AHCMS05) were resuspended (using a minimal 
amount of ethanol for wetting of the microspheres) in 
5% wlv glucose solution. After 2 h of rotation at 4°C in 
the dark, the microspheres were centrifuged and the 
supernatant, which contained free ADR in the case of 
ADR-AHCMS, was decanted. Fresh glucose solution 
(0.5 ml) was added and the suspensions were adminis- 
tered to male Wag/Rij rats using the following surgical 
procedure. Under ether anaesthesia, a midline laparot- 
omy was performed and the mesentery of the small 
intestine was exposed. The suspensions were then 
slowly injected into a mesenteric vein (intraveno- 
portal: i.v.p.) under microscopic vision with a 30- 
gauge needle. Afterwards, the vein was ligated. Then 
the syringe was refilled with 0.5 ml of 5% w/v glucose 
solution and the microspheres that remained in the 
syringe after the first injection were injected into 
another mesenteric vein. 
At 3, 7, 14 and 28d after i.v.p. adminis~ation of 
microspheres, rats (n = 2 per time point) were 
anaesthetized by i.p. injection of 2ml of pentobarbital 
solution (60mg/ml; Nembutal’K’, Sanofi, France) and a 
laparotomy was performed. The livers were perfused 
via the portal vein with phosphate buffer (O.lM, pH 
7.4) to rinse the vascular system followed by 
perfusion-fixation buffer (2% glutaraldehyde in 
phosphate buffer, 0.1 M, pH 7.4), which allowed 
fixation of the tissues in situ. Subsequently, the rats 
were killed and the liver tissue was prepared for light 
microscopy by embedding in Technovit 7100’~ 
(Kulzer, Wehrheim, Germany)14. After embedding, 
2 pm microtome sections were cut perpendicular to the 
surface of the liver lobe and stained with toluidine 
blue and alkaline fuchsin’5. 
To determine the in viva degradation rate of the 
microspheres, the number of microspheres in 
100~~rn x 100gm areas of the light microscope liver 
sections were counted. Per section, microspheres were 
counted in two times ten 100pm x lOO/lrn areas in 
two rows, as shown in Figure 1. These numbers were 
ouier inher 
row row 
Figure 1 Schematic representation of a liver section with 
two rows of IOOpm x 100j~rn counting areas for determina- 
tion of the average numbers of microspheres and mitotic 
figures per 100pm x 1OOpm area. The first row (black 
squares, outer row) is at the outermost region of the liver, 
the second row (white squares, inner row) 300pm below 
the liver surface. 
averaged per row. For each liver, six sections were 
evaluated, two in each of the large liver lobes and one 
in each small lobe. Next to the number of 
microspheres, the mitotic activity was determined as a 
measure for the regeneration of damaged tissue by 
counting the number of mitotic figures in the 
100 pm x 100 pm areas. 
For transmission electron microscopy, selected parts 
of the liver lobes were washed with PBS and postfixed 
with 1% 0~0~ in PBS. After dehydration in a graded 
ethanol series, samples were embedded in Epon 812. 
Ultrathin sections were cut and examined for cellular 
interactions with microspheres in a Philips 201 
Transmission Electron Microscope, operated at 40 kV. 
Liver damage due to the administration of 
microspheres was also monitored by measuring the 
levels of liver damage marker enzymes at 0, 1, 3, 7, 14 
and 28 d after administration of AHCMS (n = 2) or 
ADR-AHCMS (n = 2) to male Wag/Rij rats. Controls 
(n = 2) received a sham operation and were adminis- 
tered 1 ml of 5% w/v glucose solution. Plasma levels of 
alkaline phosphatase, serum glutamate oxaloacetate 
~ansaminase (SGOT), serum glutamate pyruvate 
transaminase (SGPT), ?;-glutamyl transferase (y-GT) and 
lactate dehydrogenase (LDH) were determined at the 
Clinical Chemical Laboratory of the Antoni van 
Leeuwenhoek Huis (Amsterdam, The Netherlands). 
RESULTS AND DISCUSSION 
The matrices of AMS and AHCMS consist predomi- 
nantly of albumin. Since this is an endogenous 
material which is readily metabolized in the body, it 
may be expected that the microspheres are degraded 
by proteolytic enzymes. A preliminary study of the in 
vi&o enzymatic degradation of AMS, in which the 
degradation time was taken as the time at which single 
microspheres could no longer be detected using a light 
microscope, was not suitable to obtain quantitative 
results and only some general trends could be 
observed. Table 1 shows that the degradation was 
strongly influenced by the cross-linking of the 
microspheres. 
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The degradation time increased with higher glutar- 
aldehyde concentrations and longer cross-link times. 
Trypsin is known to act specifically on the carboxylic 
acid side of basic amino acids such as lysine and 
arginine’“. Since lysine residues were modified 
during microsphere preparation’, the efficacy of this 
enzyme was reduced with increasing cross-linking 
density. At 3% glutaraldehyde, no degradation of 
AMS was observed within 48 h. Even though protei- 
nase K is not amino acid-specific (although the 
carboxylic acid side of aromatic or hydrophobic 
amino acids is preferred), the degradation rate was 
also decreased with increasing glutaraldehyde 
content. At any applied cross-linked concentration, 
however, microspheres could be degraded. 
In the second set of experiments, the degradation of 
AHCMS and AMS was followed using turbidity and 
heparin release measurements. Figure 2 shows that 
AHCMSOS could also be degraded by trypsin. 
Enzymatic activity was evident since with increasing 
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Figure 2 Degradation of AHCMS05 in trypsin solutions of Figure 3 Degradation of AHCMS or AMS in trypsin solution 
varying activity as determined by BAEE assay, at 37°C. of 931 U/ml at 37°C as determined by: a, turbidity of 
a, Turbidity of microsphere suspension and b, heparin microsphere suspension; b, heparin release as measured 
release as measured by Azure A method. 0, 931 U/ml; by Azure A method. 0, AHCMS02; A, AHCMS05; 
A, 433 U/ml; 0, 149 U/ml. 0, AHCMSIO; A, AMSOS. 
enzyme concentrations, i.e. with increasing enzyme 
activity as determined by a BAEE assay, the degrada- 
tion rate increased. Furthermore, in PBS no degrada- 
tion of AMS and AHCMS was observed. Figure 2 also 
shows that turbidity and heparin release changed 
accordingly. With longer degradation times, the 
number of particles decreased and the turbidity of the 
suspension also decreased (Figure ~a). Heparin is not 
degraded by trypsin or proteinase K, and therefore 
heparin which may be linked to protein degradation 
products of low molecular weight will be released 
during degradation (Figure ~b). Both parameters, 
decrease of turbidity of the suspension as well as 
heparin release, indicated microsphere degradation. 
From Figures 2 and 3 it can be seen that these 
parameters reached plateau values at approximately 
the same time. The effect of the cross-link density of 
AMS on the degradation rate of these microspheres, 
shown in Table 1, was also observed with AHCMS. 
Figure 3a and b shows the degradation of AHCMSOB, 
q 
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AHC~SO5, AHC~SlO and AMSO in a trypsin solution 
of 931 U/ml, as determined by the turbidity and the 
heparin release, respectively. With increasing glutar- 
aldehyde content, the plateau values of both the turbid- 
ity and the heparin release were reached at longer time 
intervals. In the case of AMS, no heparin release was 
detected, as expected. 
AHCMS degradation in proteinase K solutions showed 
the same trends. Figure 4 shows the turbidity and the 
heparin release of an AHCMSOS suspension during the 
degradation in a proteinase K solution of 0.005mglml 
at 37°C. 
Light microscopic analysis (Figure 5) of the 
microspheres during this degradation process showed 
several stages. Initially, the spherical geometry of the 
microspheres was evident (Figure 5~). At this stage the 
azure A assay already indicated some heparin release. 
During the degradation process, the microspheres 
became disrupted (Figure .!ib), while the turbidity 
decreased and the heparin release increased. Although 
disruption was already manifest, the microspheres 
retained their size. At the third stage (Figure 5~) the 
microspheres had become totally disrupted, losing 
their spherical geometry. Finally, almost all particulate 
material had disappeared (Figure 56). During the last 
two stages, heparin release and turbidity barely 
changed. 
The existence of several phases in the degradation 
behaviour of AMS has been described previously. 
Willmott et a1.17 assessed the in vitro degradation of 
AMS in trypsin solution by laser diffraction using 
changes in volume concentration, which is computed 
from both amount of light transmitted and particle size 
dis~ibution. They found a latent period before the 
particles appeared to ‘swell’ and degrade. In laser 
diffraction measurements, however, the size or size 
distribution is calculated by deconvolution of the 
scatter pattern. The scatter pattern is influenced by the 
size of the particles, the shape of the particles, the 
homogeneity of the particles and the relative refractive 
index: nparti&nmedium. Changes in the volume concen- 
trations can be caused by changes in either one of these 
parameters. Bearing this in mind, the latent phase 
would correlate with the phase depicted in Figure 5a 
and to a lesser extent with the phase shown in Figure 
P 
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Figure 4 Degradation of AHCMSOS in a proteinase K 
solution of 0.005 mglml at 37°C as determined by: 0, turbid- 
ity and n , heparin release. 
Figure 5 Light micrographs of AHCMSO5 during in vitro 
degradation in proteinase K solution (O.O05mg/ml) at 37°C. 
Bar indicates 28.3pm. 
5b. The second phase, the apparent swelling phase, 
could also be induced by the disruption of the particles 
without any change in size, correlating with the 
degradation phases shown in Figure 5b and c. 
Table 2 shows the results of the third set of in vitro 
degradation experiments. In these experiments, the 
time at which 75% of the particles were smaller than 
10pm as determined using a flow cytometer was taken 
as a measure of the degradation time. Table 2 shows 
that the microspheres were easily degraded by protein- 
ase K, which is in agreement with the previous experi- 
ments. Under these experimental conditions, however, 
there is hardly any in~uence of the cross-link density 
on the degradation time. In the ease of heparinase 
there was no sign of macroscopic degradation. During 
the experiment, however, it was observed that the 
microspheres became sticky, which resulted in a slight 
increase of the size of the measured particles. This 
Table 2 Degradation time* (h) of albumin and albumin- 
heparin conjugate microspheres by different enzyme systems 
determined using flow cytometry 
Proteinase K Heparinase Tritosomes 
AMS02+ 2.5 n.d.$ 16 
AMSOS 3 n.d. 28 
AMSlO 3 X4 
AHCMS02 2.5 X ii 
AHCMS05 3 X 20 
AHCMSlO 3 X X 
“The time at which 75% of the particles were smaller than IOpm. 
‘Number in codes refers to glutaraldehyde concentration. 
‘n.d., not determined. 
I’x, no degradation within time of experiment. 
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indicates that degradation of the heparin will not result 
in destruction of the microspheres, implying that the 
microspheres are stabilized by cross-linking of the 
protein chains. In the case of degradation by tritosomal 
enzymes, the microspheres cross-linked with 0.2 and 
0.5% glutaraldehyde were degraded, whereas micro- 
spheres cross-linked with 1.0% glutaraldehyde did not 
show any signs of degradation in this experimental set 
up. This, once more, illustrates the effect of the cross- 
link density on the degradation behaviour. Overall, 
these results indicate that the microspheres are in 
principle susceptible to degradation in vivo, either 
upon endocytosis or after excretion of lysosomal 
enzymes in the vicinity of the microspheres. 
In tivo degradation was studied by determination of 
the amounts of microspheres in liver tissue after i.v.p. 
administration of empty AHCMSOS and ADR-loaded 
AHCMSOS. Using the described injection procedure, 
approximately 95% of the microspheres were injected. 
It has been shown previously that, after intravascular 
administration, particles larger than 7-12pm are 
trapped in the first capillary bed encountered, and that 
drug-loaded particles of this size can in principle be 
used for site-specific targeting of cytostatic agents*‘. 
AHCMSOS which were sieved using 10 and 25@m 
sieves swell to a size of approximately lo-50pm upon 
suspension in an aqueous medium’. The light 
micrograph in Figure 6 shows that these particles are 
trapped in the vascular system of the liver after 
administration into a mesenteric vein. 
To determine the site of en~apment of the 
microspheres, the histological organization of the liver 
has to be clarified. Figure 7 shows a schematic 
representation of the architecture of the liver. Two 
different concepts have been distinguished. In the first 
concept, the classical lobule is the main building block 
of the liver lg. The classical lobule consists of a hexag- 
onal structure with the corners of the polygon 
occupied by portal canals. These portal canals consist 
of a small branch of the portal vein and one of the 
hepatic artery, as well as a bile ductule, enclosed in a 
common investment of connective tissue. The 
branches of the portal vein in the portal canals may be 
Figure 6 Light micrograph of ADR-loaded AHCMS05 (at 
arrows) trapped in terminal portal veins of the hepatic 
vascular system, 1 h after i.v.p. injection into a male Wag/ 
Rij rat. Bar indicates 37.4pm. 
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Figure 7 Schematic representation of the architecture of 
the liver. 
up to 280pm in diameter. Blood enters the hepatic 
sinusoids from small branches of the hepatic artery 
and portal vein, flows centripetally through the liver 
lobules and leaves via the central vein. In the second 
concept, first described by Rappaport et dzo, the 
building block is the acinus, which is the smallest 
structural and functional unit. The acinus is a mass of 
parenchymal tissue, associated with a fine terminal 
branch of the portal vein (terminal portal vein). These 
branches leave the portal canals at intervals and run 
along the side of the classical lobule. Terminal portal 
veins are accompanied by very sparse connective 
tissue, terminal branches of the hepatic artery, and the 
bile duct and a fine network of lymphatics’g. 
The micrographs depicted in Figure 8 show liver 
sections at 3 and 7d after i.v.p. administration of 
empty AHCMSOS. The micrographs show that the 
microspheres are trapped in the terminal portal veins 
of the liver. AHCMSOS of lo-5Oym diameter are too 
large to pass through the terminal branches of the 
portal vein and will be trapped in these branches. 
Almost all of the microspheres were located inside 
these small blood vessels. Occasionally, a small 
microsphere was observed within a sinusoid [see also 
Figure 21). Most AHCMS05 were detected in the 
peripheral regions of the liver lobes. Towards the 
periphery of the liver, blood vessels become more 
branched and are smaller in diameter. With decreasing 
size of the particles, entrapment will shift from the 
central parts of the liver towards the periphery. This is 
also depicted in Figure 9, showing the average number 
of AHCMSOS and ADR-AHCMSOS in 100 pm x 100 pm 
areas of the liver lobes, Areas at the outmost region of 
the liver (outer row) as well as areas 300pm under the 
liver surface (inner row) were evaluated. 
There was a distinct difference between the number 
of spheres in the outer row and in the inner row of the 
liver, with most microspheres being observed in the 
outer row. Figure 9 also shows that the number of 
spheres in these rows was not significantly altered if 
ADR-loaded AHCMS were used instead of empty 
AHCMS. 
Figure 9 and the micrographs shown in Figure 8 
show a decrease in the number of microspheres in 
the liver tissue in time. The highest number of 
spheres was observed at day 3 post-adminis~ation 
Biomaterials 1994, Vol. 15 No. 8 
Albumin-heparin conjugate microspheres: H.F.M. Cremers et al. 583 
Figure 8 Histological sections of liver tissue after injection 
of AHCMS05 (indicated by arrows) into a mesenteric vein of 
male WaglRij rats. a, 3 d after injection; b, 7 d after injection. 
Bar indicates 37.5,~m. 
(the first day of examination), then numbers gradually 
decreased, and at day I4 hardly any microspheres 
could be found. At day 28 no microspheres could be 
detected. 
From the decrease of the mean number of 
microspheres per 100pm x 100pm area (per time 
point, per row), an intrahepatic half life of approxi- 
mately 1 d was calculated for both empty and ADR- 
loaded AHCMSOS. Willmott et a1.17 previously 
determined the half life of radiolabelled AMS, cross- 
linked with 3.5% glutaraldehyde, to be 3.6 d. 
It was demonstrated that AHCMS could be degraded 
in vitro by lysosomal enzymes. The light micrographs 
shown in Figure 8 suggest an increased cellular 
activity surrounding the particles in the terminal 
portal veins. Terminal portal veins are sparsely 
surrounded by connective tissue, therefore the 
increased cellular activity is mainly due to the infiltra- 
tion of macrophages/Kupffer cells. This was confirmed 
by transmission electron micrographs, as shown in 
Figure 10. 
Engulfment of microspheres by macrophages/Kupffer 
cells is also demonstrated in Figure 11. This figure 
shows a transmission electron micrograph of a small 
microsphere which is engulfed by a phagocytic cell, 
10 r . 
7 14 28 
Time (d) 
Figure 9 Number of microspheres counted in 
100pm x 1OOpm areas of the liver tissue after i.v.p. 
administration of AHCMS05 or ADR-AHCMS05 as a 
function of time. Each point represents the average number 
of microspheres in 10 areas in one section. 0, AHCMSOS, 
outer row; 0, AHCMS05; inner row; n , ADR-AHCMSOS, 
outer row; 0, ADR-AHCMS05, inner row. 
Figure 10 Transmission electron micrograph from 
albumin-heparin conjugate microspheres, cross-linked 
with 0.5% glutaraldehyde, lodged in the liver, 3d post- 
administration. The microspheres present in terminal 
portal veins are surrounded by macrophages/Kupffer cells. 
Bar indicates 2.9pm. 
lodged in a sinusoid. The lysosomal compartments are 
all situated near the microsphere surface. These 
findings suggest that the microspheres are exposed to 
enzymatic degradation upon engulfment by macro- 
phages/Kupffer cells. 
The in vitro degradation experiments showed that the 
microspheres were disrupted during enzymatic 
degradation. Figure 8b shows AHCMS which were 
partly degraded. It may be conceived that smaller parts 
of destructed microspheres which are not engulfed by 
phagocytic cells flow through the small branches of 
the portal veins during the in vivo degradation process. 
If these parts are large enough, they will be trapped in 
the sinusoids or the lungs. However, no microsphere 
fragments were found in the sinusoids, nor were traces 
of microspheres found on examination of the lungs at 
days 14 and 28. In conclusion, these observations 
suggest that the microspheres were probably degraded 
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Figure 11 Transmission electron micrograph from an 
albumin-heparin conjugate microsphere, cross-linked with 
0.5% glutaraldehyde, lodged in the liver, 3d post-admin- 
istration. The microsphere, present in a sinusoid, 
surrounded by hepatocytes, is engulfed by a Kupffer cell. 
Lysosomal compartments of the cell (at arrows) are fusing 
with the microsphere-containing vacuole. Bar indicates 
0.65pm. 
upon phagocytosis of the entire particle, or by excretion 
of lysosomal enzymes, yielding soluble products and/or 
microsphere debris. These results are in good 
agreement with data previously published by Willmott 
et ~1.'~. During the degradation of “‘1-AMS, no 
accumulation of radiolabel was found in the lungs, 
Protein microspheres, when degraded in the liver, did 
not appear to relocate to any marked extent to 
‘downstream’ organs such as lungs and bone marrow. 
The authors concluded that the originally entrapped 
particles are not eroded to particles of smaller 
diameter and that a more likely explanation is that the 
particles are degraded into soluble protein/peptide 
fragments at the site of entrapment. 
The tissue reaction caused by the microspheres may 
be considered to be very mild. The increased 
macrophage/Kupffer cell activity around the 
microspheres, shown in Figures 8 and 20, suggests that 
the microspheres provoked a foreign body reaction, 
which is defined as ‘a variation in normal tissue 
behaviour caused by the presence of a foreign body’21. 
The foreign body reaction was localized and ended as 
soon as the microspheres were degraded. No further 
signs of acute or chronic inflammatory responses were 
observed. Moreover, the mitotic activity of the livers 
was evaluated as a measure of the regeneration of 
damaged tissue. Compared with controls, which did 
not receive any treatment, no increase in mitotic 
activity was found (data not shown). 
The biocompatibility of the microspheres was also 
evaluated by monitoring the plasma levels of liver 
damage marker enzymes. In Figure 12, the enzyme 
levels are presented relative to the enzyme levels in 
control animals, which were injected with 1 ml of 
5% w/v glucose solution. Except for SGPT levels at 
day 1, the levels of the marker enzymes were barely 
increased as compared with the controls. This suggests 
0 7 14 21 28 
a Time (d] 
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Figure 12 Levels of damage marker enzymes, relative to 
levels in control animals which were injected with 5% w/v 
glucose solution. a, AHCMSOS; b, AD&AHCMSOS. 
0, Alkaline phosphatase; 0, serum glutamate oxaloace- 
tate transaminase (SGOT); 0, serum glutamate pyruvate 
transaminase (SGPT); B, y-glutamyl transferase (?I-GT); 
& lactate dehydrogenase (LDH). 
that the microspheres, with or without ADR, cause 
little damage to the liver, as far as this can be 
determined from these biochemical parameters. 
In conclusion, these results indicate that injection of 
AHCMSOS into the liver has minimal effects on the 
liver tissue, possibly with little effect on the liver 
function or little clinical liver damage. Incorporation 
of ADR into the microspheres did not change these 
results. This is probably due to rapid elimination of 
the ADR in the liver. It was demons~ated that after 
administration of ADR-AHCMS to male WaglRij rats, 
at a dose of 5 mg ADR/kg, which is comparable to the 
dose administered in these experiments, the ADR liver 
tissue levels had decreased from 37 ,ug/g at 15 min after 
administration to ap 
! 
roximately 
after administration’ 
5 pglg of tissue at 4 h 
. Rapid elimination of ADR was 
also observed in humans, where 50% of the drug is 
eliminated during the first transit through the liverz3. 
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Moreover, only mild liver cell changes have been 
demonstrated after anthracycline treatment and they 
could have been secondary to damage of other tissues. 
However, mechanisms of anthracycline toxicity are 
poorly understood and it has been demonstrated that 
rat hepatocytes are more sensitive to ADR than human 
hepatocytes, at 24 h exposure to ADR in culturez4. 
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CONCLUSIONS 
8 
In vitro degradation experiments showed that AHCMS 
can be degraded by proteolytic enzymes via degrada- 
tion of the protein moieties of the matrix. The in vitro 
degradation rate is mainly controlled by the cross-link 
density of the microspheres, and decreases with 
increasing degree of cross-linking. 
Upon i.v.p. injection into the liver, the microspheres 
are trapped in the hepatic vascular system, mainly at 
the periphery of the liver. The microspheres are 
degraded at the site of entrapment by cellular 
enzymatic processes. No adverse effects as measured 
by liver damage marker enzymes and signs of 
prolonged chronic inflammatory responses or 
increased mitotic activity were observed, indicating 
that the carrier is well tolerated after intrahepatic 
administration. Incorporation of adriamycin in the 
carrier did not change these findings. In conclusion, 
these results suggest that ADR-loaded AHCMS can in 
principle be used in the treatment of liver metastases 
or in adjuvant therapy, without damaging the liver. 
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